Polomar Health Services (PMHS) Net Margin (2022 - 2026)
Polomar Health Services (PMHS) posted Net Margin of 7.29% for Q2 2026, up 388.94% on a QoQ basis from 2.52% in Q1 2026, and up 1107791.0% year-over-year from N/an in Q2 2025.
Powered by 
Analysis
Polomar Health Services (PMHS) Net Margin (2022 - 2026) Analysis & Trends
Polomar Health Services has reported Net Margin for 5 years, with the latest figure at 7.29% in Q2 2026.
- On a quarterly basis, Net Margin rose 1107791.0% year-over-year to 7.29% in Q2 2026; TTM through Jun 2026 was 301.11%, a 473815.0% increase from a year earlier, with the FY2025 full-year figure at 1650.82%, up 62943.0% from the prior year.
- Net Margin was 7.29% for Q2 2026 at Polomar Health Services, up from 2.52% in the prior quarter.
- The five-year high for Net Margin was 7.29% in Q2 2026, with the low at 11070.62% in Q2 2025.
- Average Net Margin over 5 years is 3123.15%, with a median of 1247.48% recorded in 2024.
- The sharpest annual moves came in 2025 and 2026: Net Margin tumbled 975471 bps in 2025, then jumped 1107791 bps in 2026.
- Over 5 years, Net Margin stood at 506.59% in 2022, then soared by 34 bps to 332.87% in 2023, then tumbled by 935 bps to 3444.13% in 2024, then jumped by 59 bps to 1422.17% in 2025, then surged by 101 bps to 7.29% in 2026.
- The last three Net Margin figures came in at 7.29% (Q2 2026), 2.52% (Q1 2026), and 1422.17% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.69 Bn | 2.15 Bn | -13.91% |
| 2 | Viatris | 18.87 Bn | 17.98 Bn | 1.46 Bn | -3.16% |
| 3 | Dr Reddys Laboratories | 9.74 Bn | 9.57 Bn | 396.53 Mn | 5.50% |
| 4 | Amneal Pharmaceuticals | 5.41 Bn | 5.28 Bn | 334.51 Mn | 8.74% |
| 5 | Bausch Health Companies | 2.30 Bn | 458.88 Mn | 2.10 Bn | 9.12% |
| 6 | Alvotech | 1.53 Bn | 1.39 Bn | 2.56 Mn | -121.81% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 9.28% |
| 8 | Amphastar Pharmaceuticals | 1.02 Bn | 726.78 Mn | 93.47 Mn | 16.50% |
| 9 | Fennec Pharmaceuticals | 393.81 Mn | 352.56 Mn | 17.15 Mn | 11.04% |
| 10 | Polomar Health Services | 5.66 Mn | 5.48 Mn | 935,916.00 | 7.29% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.29% |
| Mar 31, 2026 | -2.52% |
| Dec 31, 2025 | -1,422.17% |
| Sep 30, 2025 | -10,543.16% |
| Jun 30, 2025 | -11,070.62% |
| Mar 31, 2025 | -10,058.45% |
| Dec 31, 2024 | -3,444.13% |
| Sep 30, 2024 | -2,754.93% |
| Jun 30, 2024 | -1,315.92% |
| Mar 31, 2024 | -1,179.04% |
| Dec 31, 2023 | -332.87% |
| Sep 30, 2023 | -802.36% |
| Dec 31, 2022 | -506.59% |
| Sep 30, 2022 | -298.67% |